Company Overview - Medifast (MED) is anticipated to report a year-over-year decline in earnings due to lower revenues, with a consensus estimate indicating a quarterly loss of $0.76 per share, representing a significant change of -860% compared to the previous year [3][12] - Revenues for the upcoming quarter are expected to be $70.81 million, reflecting a decrease of 40.5% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on February 17, and the stock may experience upward movement if the reported numbers exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised 40% higher in the last 30 days, indicating a reassessment by analysts [4] Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model shows that the Most Accurate Estimate for Medifast aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12] - Despite a Zacks Rank of 2 (Buy), the combination of a 0% Earnings ESP makes it challenging to predict a positive earnings surprise for Medifast [12] Historical Performance - In the last reported quarter, Medifast was expected to post a loss of $0.01 per share but instead reported a loss of -$0.21, resulting in a surprise of -2,000% [13] - Over the past four quarters, Medifast has only beaten consensus EPS estimates once [14] Industry Context - In comparison, US Foods (USFD), a player in the Zacks Food - Miscellaneous industry, is expected to post earnings of $1 per share for the same quarter, indicating a year-over-year increase of +19.1% [18] - US Foods' revenue is projected to be $9.86 billion, up 3.9% from the previous year, with a positive Earnings ESP of +1.13% and a Zacks Rank of 3 (Hold), suggesting a higher likelihood of beating the consensus EPS estimate [19][20]

Core Viewpoint - The market anticipates Waystar Holding (WAY) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Waystar is expected to post quarterly earnings of $0.39 per share, reflecting a year-over-year increase of +34.5% [3]. - Revenues are projected to reach $294.61 million, which is a 20.7% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.52% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Waystar is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.82%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Waystar currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Waystar exceeded the expected earnings of $0.34 per share by delivering $0.37, resulting in a surprise of +8.82% [13]. - Over the past four quarters, Waystar has beaten consensus EPS estimates three times [14]. Industry Comparison - Another player in the industry, Pinterest (PINS), is expected to report earnings of $0.66 per share, with a year-over-year change of +17.9% and revenues of $1.33 billion, up 15.2% from the previous year [18]. - Pinterest's consensus EPS estimate has been revised down by 60.6% over the last 30 days, leading to an Earnings ESP of -3.64%, making it challenging to predict a beat on the consensus EPS estimate [19].

Core Viewpoint - The market anticipates a year-over-year decline in Watsco's earnings due to lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Watsco is expected to report quarterly earnings of $1.94 per share, reflecting an 18.1% decrease year-over-year, and revenues of $1.61 billion, down 8.3% from the previous year [3]. - The consensus EPS estimate has been revised down by 8.61% over the last 30 days, indicating a bearish sentiment among analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a negative Earnings ESP of -3.69% for Watsco, suggesting analysts have become more pessimistic about the company's earnings prospects [12]. - Watsco currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Watsco was expected to earn $4.21 per share but only achieved $3.98, resulting in a surprise of -5.46% [13]. - Over the past four quarters, Watsco has only beaten consensus EPS estimates once [14]. Comparative Industry Analysis - Ingersoll Rand, another player in the manufacturing industry, is expected to post earnings of $0.91 per share, indicating an 8.3% year-over-year increase, with revenues projected at $2.05 billion, up 7.8% [18][19]. - Ingersoll Rand has a positive Earnings ESP of +0.82% and a Zacks Rank of 3, suggesting a higher likelihood of beating consensus EPS estimates [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year decline in FirstEnergy's earnings despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - FirstEnergy is expected to report quarterly earnings of $0.52 per share, reflecting a year-over-year decrease of 22.4% [3]. - Revenue projections stand at $3.24 billion, which is a 2% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from analysts [4]. - The Most Accurate Estimate for FirstEnergy is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.26%, suggesting a bearish sentiment among analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is stronger for positive readings [8][9]. - FirstEnergy's current Zacks Rank is 2 (Buy), but the negative Earnings ESP complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, FirstEnergy exceeded earnings expectations by delivering $0.83 per share against an expected $0.76, resulting in a surprise of +9.21% [12]. - Over the past four quarters, FirstEnergy has beaten consensus EPS estimates three times [13]. Industry Comparison - Eversource Energy, another player in the utility sector, is expected to report earnings of $1.11 per share, marking a year-over-year increase of 9.9% [17]. - Eversource's revenues are projected at $3.53 billion, up 18.9% from the previous year, with a positive Earnings ESP of +1.27% and a Zacks Rank of 2, indicating a higher likelihood of beating estimates [18][19].

Core Insights - Enbridge Inc. (ENB) is scheduled to report its fourth-quarter 2025 results on February 13, 2026, with earnings estimated at 60 cents per share and revenues at $11.8 billion, indicating a 1.3% year-over-year improvement [1][8] Financial Performance - ENB has beaten consensus earnings estimates in three of the last four quarters, with an average surprise of 1.76% [2] - The company has an Earnings ESP of -1.01% and a Zacks Rank of 3 (Hold), suggesting a lower likelihood of an earnings beat this quarter [4] Revenue Generation - ENB is expected to have stable fee-based revenues due to its midstream business model, which is less affected by oil and natural gas price volatility [6] - The Gas Transmission business unit is anticipated to contribute significantly to earnings, alongside the Liquid Pipelines segment [6] Market Performance - ENB's stock has increased by 11.9% over the past year, underperforming the industry average of 13.8% and Kinder Morgan's 15.7% increase [9] - The company's current EV/EBITDA ratio stands at 15.61, which is above the industry average of 14.51, indicating a premium valuation [12] Investment Outlook - Enbridge is positioned to generate additional cash flows from over C$30 billion in secured capital projects, which include liquid pipelines, gas transmissions, and renewables [14] - The company has a strong history of rewarding shareholders with dividend increases for 31 consecutive years [15] - However, ENB's debt-to-capitalization ratio of 60.4% is higher than the industry average of 57.7%, raising concerns about its debt burden [16] Competitor Analysis - Kinder Morgan reported fourth-quarter 2025 adjusted earnings of 39 cents per share, exceeding the consensus estimate of 37 cents [17] - Enterprise Products Partners reported adjusted earnings of 75 cents per unit, beating the consensus estimate of 70 cents [17]

Core Viewpoint - Transocean Ltd. (RIG) is expected to report fourth-quarter earnings on February 19, with a consensus estimate of 9 cents per share and revenues of $1.04 billion [1][8]. Group 1: Previous Quarter Performance - In the last reported quarter, Transocean's adjusted earnings were 6 cents per share, surpassing the Zacks Consensus Estimate of 4 cents, driven by strong segment performance [2]. - Adjusted revenues for the last quarter were $1 billion, exceeding the Zacks Consensus Estimate by $21 million [2]. Group 2: Earnings Surprise History - RIG has beaten the Zacks Consensus Estimate in three of the last four quarters, with an average negative surprise of 208.33% [3]. - The Zacks Consensus Estimate for fourth-quarter 2025 earnings indicates a 200% year-over-year increase, while revenues are expected to rise by 9.08% compared to the previous year [3]. Group 3: Factors Influencing Q4 Performance - Transocean generates revenue by providing offshore drilling services, leasing specialized drilling rigs and equipment to oil and gas producers [4]. - The Ultra-Deepwater Floaters segment is projected to grow by 13.1% year-over-year, contributing approximately $763.2 million to revenues [5][8]. - However, total operating and maintenance costs are expected to rise by 4.3% year-over-year to $604 million, which may negatively impact earnings [6][8]. Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for Transocean, as the Earnings ESP is -5.88%, indicating a lower likelihood of exceeding earnings expectations [7].

Core Insights - Auna S.A. has a strong history of beating earnings estimates, with an average surprise of 93.59% over the last two quarters, indicating potential for continued performance in upcoming reports [1][2] Earnings Performance - For the last reported quarter, Auna S.A. achieved earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.15 per share by 33.33% [2] - In the previous quarter, the company reported earnings of $0.33 per share against an expected $0.13 per share, resulting in a surprise of 153.85% [2] Earnings Estimates - Recent estimates for Auna S.A. have been trending upward, with a positive Earnings ESP of +44.00%, suggesting increased analyst optimism regarding the company's near-term earnings potential [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a strong likelihood of another earnings beat [5][8] Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have historically produced positive surprises nearly 70% of the time, indicating a high probability of exceeding consensus estimates [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions and potentially more accurate predictions [7]

Core Viewpoint - Middlefield Banc Corp. (MBCN) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Earnings Performance - Middlefield Banc has a solid track record of surpassing earnings estimates, with an average surprise of 17.45% over the last two quarters [2]. - In the most recent quarter, the company reported earnings of $0.65 per share against an expectation of $0.64, resulting in a surprise of 1.56% [2]. - For the previous quarter, the consensus estimate was $0.57 per share, while the actual earnings were $0.76 per share, leading to a surprise of 33.33% [2]. Earnings Estimates and Predictions - Estimates for Middlefield Banc have been trending upward, influenced by its history of earnings surprises [5]. - The company currently has a positive Zacks Earnings ESP of +1.54%, indicating that analysts are optimistic about its earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong possibility of another earnings beat [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7]. Importance of Earnings ESP - It is crucial for investors to check a company's Earnings ESP prior to its quarterly release to enhance the likelihood of successful investment decisions [10].

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider National Energy Services Reunited (NESR) . This company, which is in the Zacks Oil and Gas - Mechanical and and Equipment industry, shows potential for another earnings beat.This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average s ...

Core Insights - The fourth-quarter earnings season is ongoing, with major pharmaceutical companies set to announce their results, including AstraZeneca, Incyte, Gilead Sciences, Vertex Pharmaceuticals, and Moderna [1] Industry Overview - Several large pharmaceutical companies such as Johnson & Johnson, Lilly, AbbVie, Biogen, Merck, and Amgen reported better-than-expected fourth-quarter results, surpassing estimates for both earnings and revenues. In contrast, Novartis and Sanofi had mixed results, with earnings exceeding estimates but revenues falling short [2] - As of February 4, 40% of companies in the Medical sector, representing 73.9% of the sector's market capitalization, reported quarterly earnings. Among these, 87.5% exceeded earnings estimates, and 75% surpassed revenue estimates. Year-over-year, earnings increased by 3.3%, while revenues rose by 9.5%. Overall, fourth-quarter earnings for the Medical sector are expected to decline by 1.5%, while sales are projected to increase by 9.1% compared to the previous year [3] Company-Specific Insights AstraZeneca - AstraZeneca's performance has been mixed, with earnings beating estimates in two of the last four quarters, meeting once, and missing once, resulting in an average surprise of 3.81%. The consensus estimate for fourth-quarter sales is $15.78 billion, with earnings expected at $2.18 per share [5] - Key medicines, particularly cancer drugs and diabetes medicine, are expected to drive fourth-quarter sales, supported by strong demand trends [7] - AstraZeneca is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [8] Incyte - Incyte has a mixed history of earnings surprises, beating estimates in three of the last four quarters, with an average surprise of 14.35%. The consensus estimate for fourth-quarter sales is $1.35 billion, with earnings expected at $1.94 per share [9] - Strong sales of Jakafi and expected growth in Opzelura sales are likely to contribute to revenue growth in the fourth quarter [11][12] - Incyte is also set to report its fourth-quarter and full-year 2025 earnings on February 10 [12] Gilead Sciences - Gilead Sciences has a mixed earnings surprise history, beating estimates in three of the last four quarters, with an average surprise of 7.80%. The consensus estimate for fourth-quarter sales is $7.57 billion, with earnings expected at $1.83 per share [13] - Increased sales from Biktarvy and Descovy, along with growth in the Liver Disease portfolio, are anticipated to drive top-line growth [14] - Gilead is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [15] Vertex Pharmaceuticals - Vertex has a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 2.01%. The consensus estimate for fourth-quarter sales is $3.17 billion, with earnings expected at $5.07 per share [16] - Revenue growth is likely to be driven by higher sales of its cystic fibrosis medicine, Trikafta, and contributions from newer drugs [18] - Vertex is set to report its fourth-quarter and full-year 2025 results on February 12 [19] Moderna - Moderna has a strong earnings surprise history, beating estimates in all of the last four quarters, with an average surprise of 31.45%. The consensus estimate for fourth-quarter sales is $661.4 million, with expected earnings showing a loss of $2.60 per share [20] - Revenue is expected to be primarily driven by sales of COVID-19 vaccines, although demand has declined recently [22] - Moderna is scheduled to report its fourth-quarter and full-year 2025 earnings on February 13 [23]